-
公开(公告)号:US20250026736A1
公开(公告)日:2025-01-23
申请号:US18823254
申请日:2024-09-03
Applicant: NOVARTIS AG
Inventor: Simone BONAZZI , Artiom CERNIJENKO , Jennifer Stroka COBB , Janetta DEWHURST , John Ryan KERRIGAN , Gary O'BRIEN , MooJe SUNG , Noel Marie-France THOMSEN , Pamela TING
IPC: C07D401/14 , A61K31/4545 , A61K31/55 , A61K45/06 , C07D405/14
Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
-
公开(公告)号:US20220363671A1
公开(公告)日:2022-11-17
申请号:US17642292
申请日:2020-09-16
Applicant: NOVARTIS AG
Inventor: Jake AXFORD , Rohan Eric John BECKWITH , Simone BONAZZI , Nicole BUSCHMANN , Artiom CERNIJENKO , Janetta DEWHURST , Aleem FAZAL , Matthew James HESSE , Lauren HOLDER , Viktor HORNAK , Hidetomo IMASE , Rama JAIN , Xianming JIN , John Ryan KERRIGAN , Julie LACHAL , Fupeng MA , Hasnain Ahmed MALIK , James R. MANNING , Daniel MCKAY , Robert Joseph MOREAU , Pierre NIMSGERN , Gary O'BRIEN , Anna VULPETTI , Ken YAMADA , Junping ZHAO
IPC: C07D405/04 , A61K31/513 , C07D471/04 , C07D413/04 , C07D401/14
Abstract: Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various target proteins.
-
公开(公告)号:US20240158374A1
公开(公告)日:2024-05-16
申请号:US18460428
申请日:2023-09-01
Applicant: Novartis AG
Inventor: Simone BONAZZI , Artiom CERNIJENKO , Jennifer Stroka COBB , Natalie Alysia DALES , Janetta DEWHURST , Matthew James HESSE , Rama JAIN , John Ryan KERRIGAN , Hasnain Ahmed MALIK , James R. MANNING , Gary O'BRIEN , Andrew W. PATTERSON , Noel Marie-France THOMSEN , Pamela YF TING
IPC: C07D403/14 , A61P7/00 , C07D405/14 , C07D417/14
CPC classification number: C07D403/14 , A61P7/00 , C07D405/14 , C07D417/14
Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
-
-